A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps.

PHASE2TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 16, 2017

Primary Completion Date

July 27, 2018

Study Completion Date

July 27, 2018

Conditions
Charcot-Marie-Tooth Disease
Interventions
DRUG

FLX-787-ODT (orally disintegrating tablet)

FLX-787-ODT taken three times daily for 28 days

DRUG

Placebo ODT

Placebo ODT taken three times daily for 28 days

Trial Locations (20)

10032

Columbia University Medical Center, New York

14642

University of Rochester Medical Center, Rochester

17033

Penn State Milton S. Hershey Medical Center, Hershey

19140

Temple University, Philadelphia

32224

Mayo Clinic, Jacksonville

32607

University of Florida, Gainesville

33612

University of South Florida, Tampa

52242

University of Iowa, Iowa City

55455

University of Minnesota, Minneapolis

63104

Saint Louis University, St Louis

66160

University of Kansas Medical Center, Kansas City

80045

University of Colorado, Aurora

84112

The University of Utah, Salt Lake City

85259

Mayo Clinic, Scottsdale

97239

Oregon Health Science University, Portland

99202

Saint Luke's Rehabilitation Institute, Spokane

06053

Hospital for Special Care, New Britain

02114

Massachusetts General Hospital, Boston

02115

Brighman and Women's Hospital, Boston

05405

University of Vermont Medical Center, Burlington

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Flex Pharma, Inc.

INDUSTRY